NEW YORK (GenomeWeb) – Ventana today said that it is collaborating with MedImmune to develop a companion diagnostic for a drug MedImmune is developing for non-small cell lung cancer.

The companion diagnostic will be an immunohistochemistry assay that aims to identify patients who express programmed cell death ligand 1. MedImmune is developing an anti-PD-L1 therapy dubbed MEDI4736, which is currently in clinical studies. The drug firm will use the Ventana assay in that study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.